Stock Events

Illumina 

€110.28
1
-€0.82-0.74% Friday 15:30

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
18.26B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

2MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Next
0.02
0.13
0.23
0.34
Expected EPS
0.04
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ILU.XETRA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pacific Biosciences of California
PACB
Mkt Cap415.33M
Pacific Biosciences offers long-read sequencing technologies that compete with Illumina's short-read sequencing platforms, providing an alternative in genomic sequencing.
Thermo Fisher Scientific
TMO
Mkt Cap207.95B
Thermo Fisher Scientific competes with Illumina in the life sciences and diagnostics market, offering a range of sequencing and genetic analysis products.
Bio-Rad Laboratories - Ordinary Shares
BIO.B
Mkt Cap8.97B
Bio-Rad Laboratories provides a variety of research and clinical diagnostic products that compete with Illumina's offerings in genomic and molecular diagnostics.
Qiagen NV
QGEN
Mkt Cap9.13B
Qiagen competes with Illumina in the provision of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research.
Roche
RHHBY
Mkt Cap170.92B
Roche Holding AG competes through its acquisition of GenMark Diagnostics and a strong portfolio in diagnostics and genomic sequencing, challenging Illumina's market share.
Agenus
AGEN
Mkt Cap2.22B
Agilent Technologies offers a range of products for genomics and molecular biology that compete with Illumina's sequencing and array technologies.
Intellia Therapeutics
NTLA
Mkt Cap2.08B
Intellia Therapeutics is involved in CRISPR technology, which, while not a direct competitor in sequencing, competes in the broader genomics market where Illumina operates.
Editas Medicine
EDIT
Mkt Cap451.47M
Editas Medicine is focused on gene editing technology, representing a competitive force in the genomics industry by offering alternative approaches to genetic analysis and modification.
CRISPR Therapeutics
CRSP
Mkt Cap4.67B
CRISPR Therapeutics is engaged in gene-based medicine, indirectly competing with Illumina by advancing the application of genomics in therapeutic development.

About

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has collaboration agreements with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer; LetsGetChecked to track COVID-19 variants in California; and Merck & Co., Inc. to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency. The company was incorporated in 1998 and is headquartered in San Diego, California.
Show more...
CEO
Employees
9800
Country
US
ISIN
US4523271090
WKN
000927079

Listings